Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#3111 Patient travel challenges in the rra of PPRT

Introduction: PRRT has been used for the treatment of advanced somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors. Most commonly used forms of PRRT are Lutetium 177 labelled DOTATATE (Lutathera, Advanced Accelerator Applications, a Novartis company) which was recently approved by U.S. Food and Drug Administration (FDA) and Yttrium 90 labelled DOTATATE. In our experience, it is not uncommon for patients recently treated with PRRT to be stopped by United States Customs and Border Protection (CBP) officers while traveling, due to the detection of residual radiation activity.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kendi A

Authors: Kendi A, Halfdanarson T, Naraev B, Mercer D, Underwood J,

Keywords: theranostics, PRRT, lutetium-177-dotatate,

#457 Comparison of Transarterial Liver-Directed Therapies (LDT) for Low-Grade Metastatic Neuroendocrine Tumors (mNETs)

Introduction: Transarterial LDT can ameliorate symptoms and improve time to tumor progression (TTP) in mNETs.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Engelman E, Leon-Ferre R, Naraev B, Sharma N, Sun S,

Keywords: hepatic, artery, embolization, chemoembolization, radioembolization, neuroendocrine, tumors,

#439 Chromogranin A (CgA) and Pancreastatin (PcSt) as Predictors of Peptide Receptor Radionuclide Therapy (PRRT) Outcomes in Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)

Introduction: CgA and PcSt are widely used in assessing response to treatment in mNETs.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Sharma N, Naraev B, Engelman E, Zimmerman M, Bushnell D,

Keywords: pancreastatin, chromogranin, peptide, receptor, radionuclide, therapy, PRRT, neuroendocrine, tumors,

#402 Single-Center Treatment Outcomes in Patients (pts) with High Grade Neuroendocrine Carcinoma of the Uterine Cervix (cNEC)

Introduction: cNEC is a rare and aggressive cancer; the best treatment is unknown.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Naraev B, Sharma N, Goodheart M, O'Dorisio T, Halfdanarson T,

Keywords: neuroendocrine, carcinoma, cervix, outcomes,

#401 Status of DNA Repair and Cell Proliferation Markers in High Grade Neuroendocrine Carcinoma of the Uterine Cervix (cNEC) Compared to Small Cell Carcinoma of the Lung (SCLC)

Introduction: Most patients (pts) with cNEC are treated with chemotherapy regimens used for SCLC due to both tumors’ histological similarity and aggressive behavior.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Naraev B, Racila E, Goodheart M, Syrbu S, O'Dorisio T,

Keywords: neuroendocrine, carcinoma, cervix, DNA, repair, proliferation, lung,